<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969523</url>
  </required_header>
  <id_info>
    <org_study_id>S001</org_study_id>
    <nct_id>NCT04969523</nct_id>
  </id_info>
  <brief_title>Effect of Es-ketamine on Postoperative Delirium Among Old Patients With Lobectomy</brief_title>
  <official_title>Effect of Es-ketamine on Postoperative Delirium Among Old Patients With Lobectomy: a Multicentre, Double-blind, Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the efficiency of es-ketamine on postoperative delirium among&#xD;
      old patients with elective lobectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to investigate the effect of IV es-ketamine vs saline on the incidence of&#xD;
      postoperative delirium. It was hypothesized that IV es-ketamine would reduce the incidence of&#xD;
      in-hospital delirium during cardiac surgery lobectomy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Delirium</measure>
    <time_frame>7 days after operation</time_frame>
    <description>Confusion Assessment Method (CAM) or CAM-ICU for patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Cognitive Assessment</measure>
    <time_frame>7 days after operation</time_frame>
    <description>Montreal Cognitive Assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>es-ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>es-ketamine 0.5mg/kg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>iv saline with the same volume of es-ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lobectomy</intervention_name>
    <description>Intravenous es-ketamine 0.5mg/kg or saline during lobectomy</description>
    <arm_group_label>es-ketamine</arm_group_label>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 years old; There is no limit on the gender, ASA (American Society of&#xD;
             Anesthesiologists )Ⅰ-Ⅲ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery, severe hepatic and renal dysfunction, shock or coma, psychiatric&#xD;
             disease or central nervous system disorder or a history of long-term use of&#xD;
             psychiatric medications, cognitive dysfunction, severe arrhythmia or bradycardia,&#xD;
             ketamine allergy,drug abuse history and used other sedatives for nearly a week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

